Brain Tumor Center

A Phase 2 Study of the Ketogenic Diet vs Standard Anti-cancer Diet Guidance for Patients With G...

Will be calculated as the number of days from the date of patient registration to the date of death.

Recruiting

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Overall survival is defined from the time of randomization to death from any cause. Patients still alive at the time of an analysis will be considered censored at their date of last contact.

Recruiting

Stereotactic Radiosurgery and Immunotherapy (Pembrolizumab) for the Treatment of Recurrent Meni...

Percentage of patients who are progression-free at the landmark of 12 months from start of treatment based on the target lesion(s) that are receiving radiation treatment will be reported. Tumor progression will be assessed using I...

Recruiting

Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2 in Subjects With Progres...

Safety and tolerability of SONALA-001 SDT Definitions of Dose Limiting Toxicities (DLTs): The DLT window is the 21-day period following the first study treatment per patient. DLTs are defined as the following events during the DLT...

Recruiting

Hyperpolarized Carbon-13 Alpha-ketoglutarate Imaging in IDH Mutant Glioma

Signal-to-noise ratio (SNR) of HP 13C-aKG will be calculated voxel-by-voxel, and within each region of interest (ROI). The parameters considered will be the mean SNR, within these ROIs. Acquisition parameters will be optimized (su...

Recruiting

Model-based Electrical Brain Stimulation

A personalized decoder is trained for each patient using the recorded neural activity and self-reports. Then this decoder is used to estimate the biomarker purely from neural activity; that is, based on neural activity, it will re...

Recruiting

RMC-5552 Monotherapy in Adult Subjects With Recurrent Glioblastoma

MTD is defined as the maximal dose at which fewer than one-third of participants experience a dose-limiting toxicity (DLT).

Recruiting

AB154 Combined With AB122 for Recurrent Glioblastoma

Adverse events will be listed individually by patient and treatment group. The number of patients experiencing each adverse event will be summarized by organ and grade. The number and percentage of patients with adverse events in ...

Recruiting

A Clinical Trial of a Hemp-Derived, High Cannabidiol Product for Anxiety in Glioblastoma Patien...

The BAI is a 21-item self-report measure used to rate subjective, somatic, and panic-related symptoms of anxiety on a scale of 0 to 3 (higher scores indicating more anxiety).

Recruiting

Behavioral Health Evaluation and Intervention Program for Patients Undergoing Craniotomy

The proportion of enrolled patients that complete all three virtual behavioral health counseling sessions from time of study enrollment to the final behavioral health counseling session, approximately 6-9 months following the part...

Recruiting